Trial · NCT00183092

CJD (Creutzfeldt-Jakob Disease) Quinacrine Study

NCT00183092, Phase 2, Completed, University of California, San Francisco; results first posted 2014-05-29

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. CJD (Creutzfeldt-Jakob Disease) Quinacrine Study. Trials, record NCT00183092. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00183092

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: CJD (Creutzfeldt-Jakob Disease) Quinacrine Study
NCT number: NCT00183092
Status: Completed
Phases: Phase 2
Enrollment: 69 participants, actual
Lead sponsor: University of California, San Francisco
Conditions: Creutzfeldt-Jakob Disease
Interventions: Quinacrine, Placebo
First posted: 2005-09-16
Last updated: 2014-06-09
Results first posted: 2014-05-29

Source ClinicalTrials.gov

Registered outcomes8

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Primary Survival	Randomization to Month-2	Participants alive after 2 months on study treatment
Secondary	Change in Mini-Mental State Examination (MMSE) After 2 Months	Baseline to Month-2	The mini-mental state examination (MMSE) is a brief 30-point questionnaire that is used to screen for cognitive impairment. In about 10 minutes it samples functions including arithmetic, memory and orientation. A score greater than or equal to 25 points (out of 30) indicates a normal cognition. Lower scores can indicate severe (≤9 points), moderate (10-18 points) or mild (19-24 points) cognitive impairment. Low to very low scores correlate closely with the presence of dementia, although other mental disorders can also lead to abnormal findings on MMSE testing.
Secondary	Barthel Score Change After 2 Months	baseline, 2 months	An ordinal scale used to measure performance in activities of daily living. Scores range from 0 (worst, fully dependent) to 100 (best, independent); higher score associated with a greater likelihood of being able to live at home with a degree of independence following discharge from hospital. 10 individual items are scored and summed to derive the overall Barthel index score. Each item may be scored 0, 5, 10 or 15; not all items use the full range of 4 possible values. The amount of time and physical assistance required to perform each item are considered in scoring each item. For subjects unable to return for month-2 visit, Barthel Index was performed via telephone.
Secondary	Change in Clinical Dementia Rating Scale Sum of Boxes (CDRS-SB) After 2 Months	Baseline, 2 months	Clinical Dementia Rating Scale Sum of Boxes (CDRS-SB). The CDR is obtained through semistructured interviews of patients and informants, and cognitive functioning is rated in 6 domains of functioning: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. Each domain is rated on a 5-point scale of functioning: 0, no impairment; 0.5, questionable impairment; 1, mild impairment; 2, moderate impairment; and 3, severe impairment (personal care is scored on a 4-point scale without a 0.5 rating available). The global CDR score is computed via an algorithm. The CDR-SB score is obtained by summing each of the domain box scores, with scores ranging from 0 to 18. A higher value and/or positive change is worse. For subjects unable to return for month-2 visit, CDRS-SB was performed via telephone.
Secondary	Change in Rankin Score After 2 Months	Baseline, 2 months	The scale runs from 0-6, running from perfect health without symptoms to death. 0 - No symptoms. 1. \- No significant disability. Able to carry out all usual activities, despite some symptoms. 2. \- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3. \- Moderate disability. Requires some help, but able to walk unassisted. 4. \- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5. \- Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6. \- Dead. For subjects unable to return for the 2-month visit, Rankin score was assessed via telephone.
Secondary	ADAS-Cog Change After 2 Months Among Survivors	Baseline, 2 months	ADAS-cog measures cognitive performance by combining ratings of 11 components (word recall, word recognition, constructional praxis, orientation, naming objects and fingers, commands, ideational praxis, remembering instruction, spoken language, word finding, comprehension) representing six areas of cognition: memory; language; orientation to time, place and person; construction of simple designs and planning; and performing simple behaviors in pursuit of a basic, predefined goal. Seven components are scored as the 'number incorrect'. For example, in the commands component, the number of five commands performed incorrectly (range: 0-5). Four components are scored from 0 (no limitations) to 5 (max limitations) as the examiner's perception of remembering instructions, spoken language ability, word finding and comprehension. Component scores are summed into a total ADAS-cog score ranging from 0-75, with low scores indicating better cognitive performance.
Secondary	Change in Phonemic Fluency (Words Beginning With Letter "D")	Baseline, 2 months	Verbal fluency tests are a kind of psychological test in which participants have to say as many words as possible from a category in 60 seconds. This category (words beginning with letter "D") is phonemic. Higher scores indicate better cognition.
Secondary	Change in Semantic Verbal Fluency (Naming Animals)	Baseline, 2 months	Verbal fluency tests are a kind of psychological test in which participants have to say as many words as possible from a category in 60 seconds. This category (naming animals) is semantic. Higher scores indicate better cognition.

Source ClinicalTrials.gov

Outcomes8

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Primary Survival	Randomization to Month-2		participants	NUMBER
SECONDARY	Change in Mini-Mental State Examination (MMSE) After 2 Months	Baseline to Month-2	Subjects still alive, who attended the month-2 visit and were willing and able to tolerate cognitive testing. 1 subject in each arm did attend the 2-month visit but did not cooperate fully with the MMSE, which was therefore not scored.	units on a scale	MEAN
SECONDARY	Barthel Score Change After 2 Months	baseline, 2 months	One surviving subject in the quinacrine arm did not attend the 2-month visit and was lost-to-followup; for a second surviving subject in the quinacrine arm, the Barthel Index was inadvertently not performed at the 2-month visit.	units on a scale	MEAN
SECONDARY	Change in Clinical Dementia Rating Scale Sum of Boxes (CDRS-SB) After 2 Months	Baseline, 2 months	For subjects still alive at month 2 and assessed at the 2-month visit or via telephone	units on a scale	MEAN
SECONDARY	Change in Rankin Score After 2 Months	Baseline, 2 months	For subjects still alive at month 2 and assessed at the 2-month visit or via telephone	units on a scale	MEAN
SECONDARY	ADAS-Cog Change After 2 Months Among Survivors	Baseline, 2 months	Subjects still alive and able to tolerate cognitive testing at Month 2 visit.	units on a scale	MEAN
SECONDARY	Change in Phonemic Fluency (Words Beginning With Letter D)	Baseline, 2 months	Subject still alive and able to tolerate cognitive testing at month 2 visit	number of words generated	MEAN
SECONDARY	Change in Semantic Verbal Fluency (Naming Animals)	Baseline, 2 months	Subjects still alive and able to tolerate cognitive testing at month 2 visit.	number of words generated	MEAN

Source ClinicalTrials.gov

Results by group16

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Primary Survival	Placebo	19		participants
Primary Survival	Quinacrine	13		participants
Change in Mini-Mental State Examination (MMSE) After 2 Months	Placebo	-6.9	Full Range -18 to 4	units on a scale
Change in Mini-Mental State Examination (MMSE) After 2 Months	Quinacrine	-3.9	Full Range -10 to 1	units on a scale
Barthel Score Change After 2 Months	Placebo	-23.2	Full Range -85 to 70	units on a scale
Barthel Score Change After 2 Months	Quinacrine	-13.2	Full Range -65 to 5	units on a scale
Change in Clinical Dementia Rating Scale Sum of Boxes (CDRS-SB) After 2 Months	Placebo	3.2	Full Range -1 to 8	units on a scale
Change in Clinical Dementia Rating Scale Sum of Boxes (CDRS-SB) After 2 Months	Quinacrine	0.3	Full Range -1 to 2	units on a scale
Change in Rankin Score After 2 Months	Placebo	0.8	Full Range 0 to 2	units on a scale
Change in Rankin Score After 2 Months	Quinacrine	0.3	Full Range -1 to 2	units on a scale

1 to 10 of 16Source ClinicalTrials.gov

See all 16 results by group

Participant flow32

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Double-blind (Baseline - Month 2)	STARTED	Quinacrine	23
Double-blind (Baseline - Month 2)	STARTED	Placebo	28
Double-blind (Baseline - Month 2)	STARTED	Study Drug (Quinacrine) During Open-Label Period	0
Double-blind (Baseline - Month 2)	STARTED	Study Drug (Placebo) During Open-Label Period	0
Double-blind (Baseline - Month 2)	Alive at Month 2	Quinacrine	13
Double-blind (Baseline - Month 2)	Alive at Month 2	Placebo	19
Double-blind (Baseline - Month 2)	Alive at Month 2	Study Drug (Quinacrine) During Open-Label Period	0
Double-blind (Baseline - Month 2)	Alive at Month 2	Study Drug (Placebo) During Open-Label Period	0
Double-blind (Baseline - Month 2)	Came in for Month 2 Visit	Quinacrine	10
Double-blind (Baseline - Month 2)	Came in for Month 2 Visit	Placebo	16

1 to 10 of 32Source ClinicalTrials.gov

See all 32 participant flow

Adverse events90

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Abdominal abscess	Gastrointestinal disorders	Placebo Random Assignment	0	28
other	Abdominal abscess	Gastrointestinal disorders	Quinacrine Random Assignment	1	23
other	Abdominal abscess	Gastrointestinal disorders	Quinacrine Open-label	0	24
other	Agitation	Psychiatric disorders	Placebo Random Assignment	1	28
other	Agitation	Psychiatric disorders	Quinacrine Random Assignment	2	23
other	Agitation	Psychiatric disorders	Quinacrine Open-label	2	24
other	Elevated Liver Function Tests	Hepatobiliary disorders	Placebo Random Assignment	0	28
other	Elevated Liver Function Tests	Hepatobiliary disorders	Quinacrine Random Assignment	3	23
other	Elevated Liver Function Tests	Hepatobiliary disorders	Quinacrine Open-label	12	24
other	Diarrhea	Gastrointestinal disorders	Placebo Random Assignment	1	28

1 to 10 of 90Source ClinicalTrials.gov

See all 90 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Placebo Random Assignment
Total, all-cause mortality	Quinacrine Random Assignment
Total, all-cause mortality	Quinacrine Open-label
Total, other adverse events	Placebo Random Assignment	9	28
Total, other adverse events	Quinacrine Random Assignment	9	23
Total, other adverse events	Quinacrine Open-label	16	24
Total, serious adverse events	Placebo Random Assignment	14	28
Total, serious adverse events	Quinacrine Random Assignment	13	23
Total, serious adverse events	Quinacrine Open-label	14	24

Source ClinicalTrials.gov

Papers6

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
5952734	BACKGROUND	PubMed
9811807	BACKGROUND	PubMed
10787002	BACKGROUND	PubMed
11504948	BACKGROUND	PubMed
12666126	BACKGROUND	PubMed
24122181	DERIVED	PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
P01AG021601	Novel Therapeutics for Prion Diseases	PRUSINER, STANLEY B	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	NATIONAL INSTITUTE ON AGING	2003 to 2013

Source NIH RePORTER

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Quinacrine vs Placebo: Primary Survival

Source Trial comparisons

Tests1

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

Test	Named as
Verbal Fluency	Secondary outcome

Source ConductCognition

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00183092

GET https://conductscience.org/api/trials/v1/NCT00183092/flow?page=2

API reference For AI assistants